Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Summary

This phase II trial studies the effects of luspatercept with or without hydroxyurea in treating patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts. Biological therapies, such as luspatercept, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Hydroxyurea may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving luspatercept with or without hydroxyurea may help doctors determine what doses of the combination is safe for patients to take and how the disease responds to the treatment.

Timeline

Start

2023-02-20

Primary completion

2023-04-17

Completion

2023-06-17

Publications

• Patnaik MM, Tefferi A. Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough. Am J Hematol. 2023 Aug;98(8):1171-1175. doi: 10.1002/ajh.27003. Epub 2023 Jun 22. No abstract available.

Drugs

Indications